Company intelligence / Profile preview

Altor BioScience Corporation

Hollywood, Florida, United Statespitchbook.com ↗

Ownership: Private
Employees: ~49
Development stage: Phase 2

Overview

Altor BioScience has developed multiple immunotherapeutic agents with its lead product Nogapendekin alfa inbakicept-pmln (IL15R agonist) receiving FDA approval on April 22, 2024. The company has completed Phase II trials for ALT-801 (p53 scTCR/IL-2 fusion) for melanoma and bladder cancer, and ALT-836 (anti-tissue factor mAb) for ALI/ARDS and solid tumors.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Cytokine-based immunotherapeuticsFusion proteinsAntibody fusion proteinsNatural killer cell therapiesSingle chain T cell receptors
Industry: Biotech

Drug pipeline

3 assets

ALT-836

2 more assets in the full pipeline.

Request access →

Partnerships

NantKwest Inc.

Beyond the preview

Go deeper on Altor BioScience Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altor BioScience Corporation.

Explore the full profile